Seek Returns

ABBV vs. GMAB: AbbVie vs. Genmab Stock Comparison

How do AbbVie (ABBV) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Genmab (GMAB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

AbbVie (ABBV) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for AbbVie (ABBV) and Genmab (GMAB)
Profile ItemABBVGMAB
NameAbbVie Inc.Genmab A/S American Depositary Shares
Country/RegionUnited StatesDenmark
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization514.92 billion USD32.98 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJanuary 2, 2013June 1, 2009
Security TypeCommon StockADR

Price Performance

Cumulative Growth

ABBV
GMAB
GSPC
Loading price history…
AbbVie (ABBV) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AbbVie (ABBV) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AbbVie (ABBV) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Total Return (1Y)37.33%91.17%
Total Return (3Y, Annualized)32.74%20.70%
Total Return (5Y, Annualized)24.73%3.98%

Risk Profile

Drawdown History

ABBV
GMAB
GSPC
Loading price history…
AbbVie (ABBV) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AbbVie (ABBV) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Volatility (1Y, Annualized)25.65%45.68%
Beta (5Y)0.210.72
Max Drawdown (5Y)-21.92%-61.79%
Avg. Volume (3M)4.76M4.09M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ABBV and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Sharpe Ratio (1Y)1.291.90
Sortino Ratio (1Y)2.023.82

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Genmab (GMAB) earns 12.07% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ABBV
--

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): ABBV does not report ROE, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

For every dollar of sales, both AbbVie (ABBV) at 15.67% and Genmab (GMAB) at 16.97% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max
18.05%
ABBV
15.67%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both AbbVie (ABBV) at 39.59% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max
83.12%
ABBV
39.59%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max
83.12%
GMAB
37.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
ROE (TTM)--12.07%
ROA (TTM)10.74%8.24%
Net Margin (TTM)15.67%16.97%
Operating Margin (TTM)39.59%37.15%
Gross Margin (TTM)73.72%92.67%

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AbbVie (ABBV) at -0.84% and Genmab (GMAB) at -9.23% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Revenue Growth (YoY)8.57%19.19%
Revenue Growth (3Y CAGR)1.75%21.23%
EPS Growth (YoY)-0.84%-9.23%
EPS Growth (3Y CAGR)-29.03%8.48%

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.87 and Genmab (GMAB) at 2.45 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ABBV
0.87
Min
0.10

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Genmab (GMAB) carries debt-to-equity ratio of 0.82 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
ABBV
--

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): ABBV does not report debt-to-equity ratio, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Current Ratio (MRQ)0.872.45
Debt / Equity (MRQ)--0.82
Net Debt / EBITDA2.212.45

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV
2.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Genmab (GMAB) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV
117.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
Dividend Yield (TTM)2.40%0.00%
Dividend Payout Ratio (TTM)117.35%0.00%

Valuation

P/E Ratio (TTM)

Both AbbVie (ABBV) at 50.05 and Genmab (GMAB) at 45.84 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max
85.34
ABBV
50.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max
85.34
GMAB
45.84
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max
58.18
Q3
25.77
ABBV
7.80
Median
7.30
Q1
3.01
Min
0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max
58.18
Q3
25.77
GMAB
7.68
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Genmab (GMAB) reports 5.36, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
ABBV
-112.34

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max
13.53
Q3
6.54
GMAB
5.36
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
AbbVie (ABBV) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Genmab (GMAB)
MetricABBVGMAB
P/E Ratio (TTM)50.0545.84
P/S Ratio (TTM)7.807.68
P/B Ratio (MRQ)-112.345.36
Free Cash Flow Yield (TTM)3.44%2.59%